Endometrial hyperplasia epidemiology and demographics: Difference between revisions
(Mahshid) |
Badria Munir (talk | contribs) No edit summary |
||
| Line 10: | Line 10: | ||
*Women of all age groups may develop endometrial hyperplasia.<ref name=lk>Endometrial Hyperplasia. Radiopedia. http://radiopaedia.org/articles/endometrial-hyperplasia-1 Accessed on March 9, 2016</ref>. | *Women of all age groups may develop endometrial hyperplasia.<ref name=lk>Endometrial Hyperplasia. Radiopedia. http://radiopaedia.org/articles/endometrial-hyperplasia-1 Accessed on March 9, 2016</ref>. | ||
*However, endometrial hyperplasia is more common in [[postmenopausal]] women. | *However, endometrial hyperplasia is more common in [[postmenopausal]] women. | ||
Most patients (75%) with endometrial cancer present with postmenopausal bleeding; however, only 10% of women with postmenopausal bleeding have endometrial carcinoma.28 The remaining women with postmenopausal bleeding have atrophic or inactive endometrium or benign endometrial conditions such as polyps. The clinical predictive model proposed by Feldman and colleagues30 (i.e., 70 years of age or older, diabetes, nulliparity, and postmenopausal status) is not predictive enough to distinguish between women with perimenopausal or postmenopausal bleeding at low versus high endometrial carcinoma risk.31 The traditional risk indicators associated with EIN/carcinoma are shown in Table 2. Most of the indicators are estrogen related, either from endogenous or exogenous sources. In women with these risk factors, the relative risk of developing carcinoma is 1.2–35.32 Experience also suggests that a significant proportion of patients fail to have these risk indicators but develop endometrial carcinoma. In these cases, either the disease may not be hormone related, or hyperestrogenism is metabolically inapparent. In a literature review, 74% of patients with adenocarcinoma of the endometrium were not obese, 58% were not nulliparous, 22% experienced menopause before age 49 years, and 43–89% were not exposed to hormone replacement therapy (HRT).33 It seems that the only constant endometrial carcinoma risk indicator is age. In women aged 65 years or older, endometrial cancer is generally aggressive and has a high mortality rate (75%) compared with that (15%) in the younger age group with hormone-related cancer.34 | |||
==References== | ==References== | ||
Revision as of 20:25, 8 February 2019
|
Endometrial hyperplasia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Endometrial hyperplasia epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Endometrial hyperplasia epidemiology and demographics |
|
FDA on Endometrial hyperplasia epidemiology and demographics |
|
CDC on Endometrial hyperplasia epidemiology and demographics |
|
Endometrial hyperplasia epidemiology and demographics in the news |
|
Blogs on Endometrial hyperplasia epidemiology and demographics |
|
Risk calculators and risk factors for Endometrial hyperplasia epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Soujanya Thummathati, MBBS [2]
Overview
Women of all age groups may develop endometrial hyperplasia.[1] However, endometrial hyperplasia is more common in postmenopausal women.
Epidemiology and Demographics
Age
- Women of all age groups may develop endometrial hyperplasia.[1].
- However, endometrial hyperplasia is more common in postmenopausal women.
Most patients (75%) with endometrial cancer present with postmenopausal bleeding; however, only 10% of women with postmenopausal bleeding have endometrial carcinoma.28 The remaining women with postmenopausal bleeding have atrophic or inactive endometrium or benign endometrial conditions such as polyps. The clinical predictive model proposed by Feldman and colleagues30 (i.e., 70 years of age or older, diabetes, nulliparity, and postmenopausal status) is not predictive enough to distinguish between women with perimenopausal or postmenopausal bleeding at low versus high endometrial carcinoma risk.31 The traditional risk indicators associated with EIN/carcinoma are shown in Table 2. Most of the indicators are estrogen related, either from endogenous or exogenous sources. In women with these risk factors, the relative risk of developing carcinoma is 1.2–35.32 Experience also suggests that a significant proportion of patients fail to have these risk indicators but develop endometrial carcinoma. In these cases, either the disease may not be hormone related, or hyperestrogenism is metabolically inapparent. In a literature review, 74% of patients with adenocarcinoma of the endometrium were not obese, 58% were not nulliparous, 22% experienced menopause before age 49 years, and 43–89% were not exposed to hormone replacement therapy (HRT).33 It seems that the only constant endometrial carcinoma risk indicator is age. In women aged 65 years or older, endometrial cancer is generally aggressive and has a high mortality rate (75%) compared with that (15%) in the younger age group with hormone-related cancer.34
References
- ↑ 1.0 1.1 Endometrial Hyperplasia. Radiopedia. http://radiopaedia.org/articles/endometrial-hyperplasia-1 Accessed on March 9, 2016